{"id":"b31e71ad-8c66-52a5-9f02-9f1ae27ffd41","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-alz-npi","predicate":"decreases_in_recorded_comparison","statement":"NPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"d6af1e89-84d8-5bbe-8ed2-c48532141ca8","mechanism_event_label":"NPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.","subject":{"id":"2d483be1-dd8d-54e4-bac4-1a364bd1488a","slug":"lemon-balm-ra-enriched-extract","display_name":"RA-enriched Melissa officinalis extract","entity_type_key":"botanical"},"object":{"id":"b35ce39a-5b0c-5c03-b8f2-d575c5697c5e","slug":"human-ad-npiq-ra-trial","display_name":"NPI-Q in the 24-week RA-extract Alzheimer trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"d6af1e89-84d8-5bbe-8ed2-c48532141ca8","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-alz-npi-event","event_type":"experimental_observation","label":"NPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.","description":"### ra-alz-npi\n\nNPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.\nDoes not establish cognitive disease modification.\nModel and exposure: Same trial; secondary neuropsychiatric endpoint, P=0.012.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. | 2020 | https://pubmed.ncbi.nlm.nih.gov/33122694/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7596544/ | https://doi.org/10.1038/s41598-020-73729-2 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"2d483be1-dd8d-54e4-bac4-1a364bd1488a","slug":"lemon-balm-ra-enriched-extract","display_name":"RA-enriched Melissa officinalis extract","entity_type_key":"botanical"},"role":"tested factor","stoichiometry":null,"state_label":"RA-rich lemon-balm extract","sequence_order":0,"notes":""},{"entity":{"id":"b35ce39a-5b0c-5c03-b8f2-d575c5697c5e","slug":"human-ad-npiq-ra-trial","display_name":"NPI-Q in the 24-week RA-extract Alzheimer trial","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"extract constituent","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA-rich lemon-balm extract\", \"comparator\": \"Placebo\", \"endpoint\": \"NPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Same trial; secondary neuropsychiatric endpoint, P=0.012.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"NPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. | https://pubmed.ncbi.nlm.nih.gov/33122694/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7596544/ | https://doi.org/10.1038/s41598-020-73729-2","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-alz-npi; Does not establish cognitive disease modification.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c43f03d9-8b82-52c7-ad08-6a3e3913b9d8","evidence_kind":"source_excerpt","locator":"Lines 457-463","start_line":457,"end_line":463,"excerpt":"### ra-alz-npi\n\nNPI-Q improved by 0.5 points with extract and worsened by 0.7 with placebo at 24 weeks.\nDoes not establish cognitive disease modification.\nModel and exposure: Same trial; secondary neuropsychiatric endpoint, P=0.012.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. | 2020 | https://pubmed.ncbi.nlm.nih.gov/33122694/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7596544/ | https://doi.org/10.1038/s41598-020-73729-2 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Same trial; secondary neuropsychiatric endpoint, P=0.012.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}